18 Members•4,119 Posts

Health

Solvonis chief scientist to address NIH addiction research forum

May 5, 2026

Ian Lyall

ImmuPharma launches regulatory push for Kapiglucagon diabetes drug

May 5, 2026

Ian Lyall

BioVie advances long COVID trial, top-line data expected by summer

May 4, 2026

Steve Darling

Inside Biotech: EZZ taps viral ingredient trend with MeTime wellness launch

May 4, 2026

Lisa Uhlman

Arovella Therapeutics board changes after shareholder requisition notice

May 4, 2026

Jonathan Jackson

Candel Therapeutics to review Phase 3 prostate cancer data in May 15 call

May 4, 2026

Angela Harmantas

NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment

May 4, 2026

Angela Harmantas

Delivra Health Brands expands LivRelief with Peak Processing Solutions partnership - ICYMI

May 2, 2026

Emily Jarvie

Orthocell's Remplir achieves 90% success rate in real-world patient data - ICYMI

May 2, 2026

Jonathan Jackson

Solvonis Therapeutics results marked a successful strategic repositioning and pipeline expansion

May 2, 2026

Proactive

Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT - Health and Biotech Week in Review

May 2, 2026

Stephen Gunnion

Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings

May 1, 2026

Emily Jarvie

Recce Pharmaceuticals advances US Army burn wound program and Indonesia Phase 3 trial in March quarter

May 1, 2026

Jonathan Jackson

Lumos Diagnostics raises $265,000 through share purchase plan as FebriDx rollout gathers pace

May 1, 2026

Lisa Uhlman

AstraZeneca falls as FDA advisers reject breast cancer drug use

May 1, 2026

Oliver Haill

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

May 1, 2026

Jamie Ashcroft

Shield Therapeutics drops as CFO exits and Medicaid concerns weigh

May 1, 2026

Oliver Haill

Imugene flags strong azer-cel response rates and ASCO milestone in March quarter update

Apr 30, 2026

Lisa Uhlman

Prescient Therapeutics advances PTX-100 trial and cell therapy platforms

Apr 30, 2026

Jonathan Jackson

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

Apr 30, 2026

Ian Lyall

Powered by RoundtableAn AI/DeFi-powered Enterprise Media Operating System. Learn more at Roundtable.io.© Roundtable 2026. By using this site you agree to the Terms of Use and Privacy Policy